Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02074995 · ClinicalTrials.gov registry record · Phase 2
Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02074995 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT02074995, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15 weeks
Interventions
- OTHER placebo
- BIOLOGICAL BVS857
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02074995
The ClinicalTrials.gov registry entry for NCT02074995 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02074995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02074995 about?
NCT02074995 is a clinical study titled "Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects". Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15 weeks
What is the current status of trial NCT02074995?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2014-02. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02074995?
The interventions under investigation include: placebo (OTHER), BVS857 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02074995?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.